Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to the EPIC (Ensuring Pathways to Innovative Cures) Act, H.R.1492/S.832. Most Favored Nation (MFN) policy activity related to the reconciliation process, H.R.1, One Big Beautiful Bill Act.
2025 · 2nd Quarter (Apr 1 - June 30)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
Filed by DESIMONE CONSULTING, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 17, 2025
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- DESIMONE CONSULTING, LLC
- Filing UUID
- 20dc7daa-a070-4103-96f0-29a88672977e
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.